Carnilis Injection
Levocarnitine Injection USP
Levocarnitine Injection USP
Levocarnitine Injection USP

CARNILIS

Description
CARNILISR [L-carnitine] is a naturally occurring substance required in mammalian energy metabolism. Plasma carnitine accounts only for approximately 1 % of the total body carnitine pool, with over 98% of carnitines present in the skeletal and cardiac muscles. Dialysis therapy can cause a decrease in both free carnitine and plasma acylcarnitines. Recent studies have shown that oral & intravenous L­carnitine plays an important role on anemia and cardiovascular disease in CKD patients.

Indication:
CARNILISRInjection is used to recommend for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.

Mechanism of action:
In humans, carnitine plays a pivotal role in energy metabolism through the transportation of long­ chain fatty acids across the inner mitochondrial membrane and in controlling the rates of beta oxidations of long-chain fatty acids with subsequent energy production.

Category: Tag:

Description

Dosage:
CARNILIS R lnjection-

ESRD Patients on Hemodialysis
The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L). Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments ( e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.

Presentation:
CARNILISR Injection

CARNILISR injection is available in 1×5 ml ampoule